{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-057420","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.135172+00:00","generated_at":"2026-06-09T03:15:25.086424+00:00","sec_items":["1.01","2.02","2.05","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rani Therapeutics cuts workforce 25%, extends cash runway into 2025; reports preliminary Q3 net loss $17-19M","bullets":["Workforce reduced ~25%; restructuring cost ~$0.3M (nearly all cash) expected Q4 2023, complete by Q1 2024.","Cash, cash equivalents and marketable securities ~$60.5M at Sept 30, 2023; cash runway extended into 2025.","Preliminary Q3 net loss $17-19M (vs $16.2M in Q3 2022); nine-month net loss $53-55M.","RT-102 Phase 2 starts Q4 2023; RT-111 Phase 1 topline Q1 2024; RaniPill HC Phase 1-ready H2 2024.","RT-101 discontinued; RT-105 and RT-110 paused; new 33,340 sq ft lease in Fremont at $95,019/month base rent."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-057420","json":"https://secwatch.observer/filing/0000950170-23-057420.json","markdown":"https://secwatch.observer/filing/0000950170-23-057420.md","text":"https://secwatch.observer/filing/0000950170-23-057420.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023057420/0000950170-23-057420-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023057420/rani-20231101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T03:15:25.086424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"73a736d979445a2b1af7c35b270553f13e3a156c","claim":"Rani Therapeutics Holdings, Inc. reported the third quarter ended September 30, 2023 results: net income between $17.0 million and $19.0 million.","evidence_excerpt":"Rani’s preliminary consolidated financial results for the third quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023057420/0000950170-23-057420-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"between $17.0 million and $19.0 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"8d3239cd779449302ef170d743e088b3dcbc5b64","claim":"Rani Therapeutics Holdings, Inc. entered into Standard Industrial/Commercial Multi-Tenant Lease - Net with BKM South Bay 240, LLC valued at $95,019.00 per month (effective 2023-11-01).","evidence_excerpt":"On November 1, 2023, Rani Therapeutics, LLC (“Rani LLC”), a subsidiary of Rani Therapeutics Holdings, Inc. (the “Company”), and BKM South Bay 240, LLC (“Landlord”) entered into the Standard Industrial/Commercial Multi-Tenant Lease - Net (the “Lease”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023057420/0000950170-23-057420-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"lease"},{"label":"Counterparty","value":"BKM South Bay 240, LLC"},{"label":"Value","value":"$95,019.00 per month"},{"label":"Effective","value":"2023-11-01"}],"fact_type":"material_agreement"},{"claim_id":"412ccd054d6eecdd48b24ed052dee41ca3caf68a","claim":"Rani Therapeutics Holdings, Inc. announced a restructuring with charges of approximately $0.3 million (reduction of the Company’s workforce by approximately 25%).","evidence_excerpt":"On November 1, 2023, the Company committed to the Restructuring, which is a plan for strategic prioritization of its programs, expansion of its manufacturing and streamlining of its business operations to support potential near-term value drivers and long-term growth. The Restructuring provides for a reduction of the Company’s workforce by approximately 25%. As a result of the Restructuring, the Company estimates that it will incur approximately $0.3 million in costs of which nearly all are cash expenditures related to severance.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023057420/0000950170-23-057420-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $0.3 million"},{"label":"Headcount","value":"reduction of the Company’s workforce by approximately 25%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}